SynthesisCancer reports (Hoboken, N.J.)2026
Efficacy and Safety of Canakinumab Compared With Standard Therapy for the Treatment of Non-Small Cell Lung Cancer (NSCLC): A Systematic Review.
Synthesis in Cancer reports (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung cancer remains a leading cause of cancer-related mortality worldwide, with few effective treatment options available for advanced stages. Canakinumab, an IL-1β inhibitor, has been investigated as a potential therapeutic agent due to its role in modulating tumor-promoting inflammation. However, its clinical efficacy and safety in NSCLC (non-small cell lung cancer) continue to be uncertain.
aimsWe aimed to evaluate the efficacy and safety of canakinumab compared with other standard therapies in NSCLC treatment. METHODS AND
resultsA systematic review was conducted in accordance with PRISMA guidelines. Four electronic databases (PubMed, Scopus, Web of Science, and Embase) were searched for clinical trials assessing canakinumab for NSCLC. Eligible studies included phase I-III clinical trials. The Synthesis Without Meta-analysis (SWiM) guidelines were followed due to substantial heterogeneity in studies. Outcomes evaluated included objective response rate (ORR), progression-free survival (PFS), overall survival (OS), major pathologic response (MPR), and treatment-related adverse events. Five clinical trials (three phase III, one phase II, and one phase IB) met the inclusion criteria, with sample sizes ranging from 88 to 1382 patients. The included studies evaluated canakinumab in four distinct clinical settings: adjuvant therapy after complete resection (CANOPY-A), first-line treatment in combination with pembrolizumab plus chemotherapy (CANOPY-1) or spartalizumab plus chemotherapy, second-line treatment in combination with docetaxel (CANOPY-2), and neoadjuvant therapy with or without pembrolizumab (CANOPY-N). Compared to standard therapies, canakinumab did not significantly improve ORR, PFS, OS, or MPR across any clinical setting. Safety analysis showed comparable adverse event rates between intervention and control groups.
conclusionDespite its promising mechanistic rationale, Canakinumab did not show significant clinical benefits in NSCLC. Although it is generally well tolerated, its role in NSCLC treatment remains uncertain. Future research should concentrate on identifying predictive biomarkers and optimizing combination strategies to enhance its therapeutic potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.